Track papers across labs, topics, and trends.
Search papers, labs, and topics across Lattice.
This paper reviews the transformative impact of AI on the pharmaceutical industry, focusing on innovations in drug discovery, clinical trials, manufacturing, and personalized medicine. Key advancements include the use of AI for accurate protein structure prediction and predictive modeling in clinical trials, which significantly enhance efficiency and success rates. However, the study also emphasizes the ongoing challenges related to data quality, algorithmic transparency, and regulatory compliance that must be addressed for broader adoption of AI technologies.
AI is revolutionizing drug discovery and clinical trials, but without rigorous validation, its potential may be undermined by ethical and regulatory hurdles.
Artificial Intelligence (AI) is increasingly transforming the pharmaceutical industry by streamlining processes across drug discovery, clinical development, manufacturing, and post-marketing surveillance. In drug discovery, platforms such as DeepMind’s AlphaFold enable accurate protein structure prediction and identification of promising drug candidates, thereby reducing timelines and costs traditionally associated with early-stage research. Clinical trials benefit from AI-driven predictive modeling, which improves patient recruitment, optimizes trial design, and enhances real-time monitoring through wearable devices and IoT sensors, ultimately increasing efficiency and success rates. In manufacturing and supply chain management, AI supports advanced forecasting, automation, and blockchain-based traceability, reducing waste and mitigating risks of counterfeit drugs. Personalized medicine is strengthened by AI tools that analyze genomic and clinical data to generate individualized treatment plans, improving therapeutic outcomes while minimizing adverse effects. Despite these advances, challenges remain in ensuring data quality, algorithmic transparency, regulatory compliance, and ethical governance. Regulatory agencies such as the FDA and EMA emphasize the need for explainable and validated AI models before widespread adoption. This review critically evaluates the innovations and limitations of AI in the pharmaceutical sector, highlighting its potential to improve healthcare delivery while underscoring the importance of rigorous validation and regulatory oversight.